As the development of CAD includes several risk factors such as hyperlipidemia, obesity, diabetes mellitus, arterial hypertension, and smoking [16], pharmacological treatment includes target antiplatelet agents such as acetylsalicylic acid, clopidogrel, and blockers of adrenergic β receptors (beta blockers), hypolipemic drugs such as statins, fibrates or proprotein convertase subtilisin/kexin type 9 (PCSK-9) inhibitors, calcium channel blockers, organic nitrates, and various antihypertensive drugs (Figure 2) [21]. Here, PCSK9 is linked to Obesity.